Finance
Immune-focused company announces Q3 net loss of $4M
Published in Clinical Trials Week, December 6th, 2004
Dynavax reported a net loss of $4.0 million for the quarter ended September 30, 2004, or $0.16 share, compared to a net loss of $4.1 million, or $2.30 per share for the same period in 2003. For the 9 months ended September 30, 2004, net loss was $10.8 million or $0.54 share compared to $12.8 million or $7.20 per share for the comparable period in 2003. The net loss per share for the 3 and 9 months ended September 30, 2004 reflects the increase in common shares outstanding as a result of the company's initial public offering in February 2004.
As of September 30,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2004-12-06)
More Articles from Clinical Trials Week
- Cardiopulmonary Bypass
Postoperative fibrinolysis in pericardial cavity characterized - Immunization
Accelerated hepatitis B vaccine schedules protect prisoners better - Kidney Transplantation
Calcineurin inhibitor-free immunosuppression improves graft outcome - Mitral Valve
Percutaneous mitral valve repair shows favorable preliminary results - Non-Hodgkin Lymphoma
Yttrium 90-labeled ibritumomab effective for NHL patients - Addiction Medicine
Company licenses oral drug to treat impulse control disorder - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
